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PERSPECTIVE
Cancer survivorship, excess body fatness and weight-loss
intervention—where are we in 2020?
Annie S. Anderson1, Richard M. Martin 2,3,4, Andrew G. Renehan5, Janet Cade6, Ellen R. Copson 7, Amanda J. Cross8,
Chloe Grimmett9, Laura Keaver10, Angela King11, Elio Riboli8, Clare Shaw 12, John M. Saxton 13, On behalf of the UK NIHR Cancer
and Nutrition Collaboration (Population Health Stream)
Earlier diagnosis and more effective treatments mean that the estimated number of cancer survivors in the United Kingdom is
expected to reach 4 million by 2030. However, there is an increasing realisation that excess body fatness (EBF) is likely to influence
the quality of cancer survivorship and disease-free survival. For decades, the discussion of weight management in patients with
cancer has been dominated by concerns about unintentional weight loss, low body weight and interventions to increase weight,
often re-enforced by the existence of the obesity paradox, which indicates that high body weight is associated with survival
benefits for some types of cancer. However, observational evidence provides strong grounds for testing the hypothesis that
interventions for promoting intentional loss of body fat and maintaining skeletal muscle in overweight and obese cancer survivors
would bring important health benefits in terms of survival outcomes and long-term impact on treatment-related side effects. In this
paper, we outline the need for studies to improve our understanding of the health benefits of weight-loss interventions, such as
hypocaloric healthy-eating plans combined with physical activity. In particular, complex intervention trials that are pragmatically
designed are urgently needed to develop effective, clinically practical, evidence-based strategies for reducing EBF and optimising
body composition in people living with and beyond common cancers.
British Journal of Cancer https://doi.org/10.1038/s41416-020-01155-2
BACKGROUND
Improvements in the early detection and treatment of cancer have
led to a dramatic increase in the number of cancer survivors—
those people alive who have been diagnosed with cancer before,
during and after treatment.1 Globally, public health surveillance
data show that 5‐year net survival rates from colon, rectal and
breast cancers have increased steadily in the majority of
developed countries,2 and, in the United Kingdom, the number
of cancer survivors is expected to reach 4 million by 2030.3 The
definition of survivors includes individuals who have been cured
by treatments or who are on the road to recovery and aiming to
reduce the risk of recurrence, as well as those living with
metastatic disease, for whom efforts are more focussed on
maximising treatment effectiveness, managing the side effects of
treatment and preserving quality of life.
As we celebrate extended cancer survivorship, however, we
must also be mindful of the co-morbid conditions,4 including
overweight and obesity characterised by excess body fatness (EBF)
that can affect the quality of those additional years. Body mass
index (BMI) is the measure most commonly used as a proxy for EBF;
the measure becomes notable when the value increases beyond
25 kg/m2 (overweight) and is deemed substantial at levels above
30 kg/m2 (obesity). It is estimated that, worldwide, 1.9 billion adults
and over 340 million children and adolescents are now living with
overweight or obesity.5 Although EBF has been identified as a risk
factor for at least 13 different types of cancer,6 its effect on cancer
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survivorship is less clear. However, the prevalence of EBF in
Western societies means that its probable influence on the quality
of cancer survivorship and the prospect of prolonged disease-free
survival after primary curative treatment cannot be ignored. The
effects of EBF on insulin resistance, systemic inflammation and
other circulating factors such as adipokines and sex hormones,
which are linked to primary cancer risk, are well-described,6 and
research into the biological mechanisms that underlie the
obesity–cancer relationship (both in tumour initiation and
progression) is ongoing.7 EBF can influence the quantity, distribu-
tion and quality of adipose tissue, which is now recognised to
comprise not just adipocytes, but also blood vessel stromal cells
and immune cells. Accordingly, the roles of adipose tissue have
been found to extend beyond triacylglycerol storage to include
(among many others) glucose and lipid metabolism, appetite
regulation and, notably, immunity and inflammation, providing
potential mechanisms by which EBF might influence cancer
survivorship and response to treatment, as well as risk.8,9
Several leading health authorities recommend the management
of excess weight (e.g., avoiding weight gain, intentional weight
loss and weight-loss maintenance) for people living with and
beyond cancer,10–12 but service provision and resources for health
behaviour change and the promotion of effective interventions
within healthcare systems is suboptimal.13 Weight management in
cancer patients has routinely been dominated by concerns about
unintentional weight loss (secondary to cancer treatments or due
to progressive disease) and low body weight. These concerns have
resulted in an emphasis on nutritional interventions to maintain or
increase weight because of the negative outcomes associated
with loss of body mass in people with advanced cancer. Nutrition-
screening tools focus on parameters of undernutrition with little
heed to the issues and adverse risk profile of patients who have
EBF at diagnosis, or who gain further weight (body fat) during
treatment and beyond.
Consideration of the health benefits of managing EBF is largely
overlooked. There is a perception that many clinicians fail to be
convinced that interventions related to EBF are a key part of
cancer care and will be beneficial to patient outcomes.13 Clinicians
might even avoid these issues because they are concerned about
evoking feelings of guilt or undermining patient–health-profes-
sional relationships (especially where BMI is a known risk factor for
the cancer site),13,14 despite opportunities (‘teachable moments’)
to address this issue during and after cancer treatment.
The influence of intentional weight loss on adipose tissue
biology is unknown. It is possible that some effects of obesity
might be imprinted, and therefore might not be reversible.7 On
the other hand, work in mouse models suggests that intentional
weight loss through caloric restriction boosts anticancer immune
surveillance and delays progression.8 It is also possible that these
biological responses could enhance treatment outcomes and risk
of disease recurrence. The importance of understanding more
about the impact of obesity on both cancer incidence and
outcomes was identified in 2020 as one of the eight research-
priority areas needed to accelerate progress in cancer manage-
ment by the American Society for Clinical Oncology.15 In this
paper, we outline the need for intervention trials to address the
issue of whether promoting intentional loss of body fat and
maintaining skeletal muscle in overweight and obese cancer
survivors would bring important health benefits in terms of
survival outcomes and long-term impact on treatment-related
side effects. Realistically, management of EBF is unlikely to
become a core part of survivorship plans, unless robust clinical
trials and subsequent clinical guidelines can be developed.
EBF AND CANCER SURVIVAL
Growing evidence from epidemiology studies indicates that
avoiding EBF might have a role in reducing cancer morbidity
and mortality worldwide. The Global Burden of Disease Study
reported (using various ecological assumptions) in 2019 that
amongst 896,040 colorectal cancer deaths occurring in 2017,
73,475 (8.2%) were attributable to a high BMI.16 A meta-analysis of
82 studies reported a 35% increase in breast-cancer-related
mortality and a 41% increase in all-cause mortality in women
with breast cancer who were obese, independent of menopausal
status.17 Similarly, meta-analyses suggest that obesity is associated
with poorer survival outcomes in bladder,18 prostate19 and
hepatocellular20 cancer patients.
The obesity paradox
Considerable debate surrounds the ‘obesity paradox’,21,22 in which
high body weight appears to be associated with survival benefits
after diagnosis of colorectal,23 endometrial24 and lung cancer.25 In
some studies, this phenomenon can be explained by the association
of obesity with less aggressive tumour subtypes, such as the
increased incidence of type 1 tumours, which have a good
prognosis, compared with type 2 tumours, which have poor
prognosis, in obese endometrial cancer patients.26 A higher
tolerance of some systemic anticancer therapies in overweight/
obese patients and the benefit of energy reserves to support the
body during the stress of anticancer therapies have also been
postulated as clinical explanations for the obesity paradox (Fig. 1). In
some cases, higher body weight might reflect greater fat-free mass
that may increase the responsiveness to treatment regimens.27
However, in many publications, the association of enhanced survival
with overweight or obese status is an artefact of methodological
issues. These issues commonly include combining cohorts of
patients with early and advanced cancer so that observational data
are confounded by disease-related weight loss (reverse causality)
and the use of heterogenous cohorts that fail to adjust for tumour
biology, stage or treatment or other confounders such as smoking.
Other reported causes of the obesity paradox outlined in Fig. 1
include detection bias, where patients undergoing medical inves-
tigation for obesity-related co-morbidities are diagnosed with
incidental early-stage cancers, and collider bias, a specific form of
selection bias demonstrated in the relationships between smoking,
cancer and obesity. Cancer patients who are not obese might have

























Fig. 1 Possible explanations for the obesity paradox. Despite
significant evidence that excess body fat (EBF) is associated with
reduced cancer survival, data from a number of studies indicate that
overweight and early obese cancer patients exhibit improved
survival—this is known as the so-called ‘obesity paradox’. Although
there are potential clinical and biological explanations for this in
specific patient groups many of these reports can be explained by
methodological mechanisms, including the inadequacy of BMI as a
measure of adiposity.
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therefore artificially strengthened between obesity and cancer
outcomes. Longer-term cohort studies that have the potential to
provide better repeated measures over time are needed. Finally,
assessment of obesity by BMI fails to take body composition, notably
body fat distribution, into account. At the most basic measurement,
this would include markers of central obesity such as waist
circumference.
Weight gain after diagnosis and survival outcomes
Data regarding weight gain after diagnosis of common cancers
add another layer of complexity to the link between EBF and
cancer morbidity and mortality. For example, whereas poorer
survival outcomes associated with weight gain are suggested for
breast cancer after diagnosis,28 current evidence for the influence
of weight gain after diagnosis on colorectal cancer survival seems
to be less clear-cut,29 notably when patients with early disease
and those with metastatic disease (and high tumour burden) are
included in the same analysis. Although some studies suggest that
a higher BMI might be associated with better survival in patients
with colorectal cancer, meta-analyses have reported little impact
on the risk of survivorship in overweight patients, whereas both
obese and underweight patients have an increased risk of all-
cause mortality, cancer-specific mortality, disease recurrence and
worse disease-free survival compared with patients of normal
weight.30 Being able to distinguish between intentional and
unintentional weight loss is also important, as is the impact of
weight loss on body composition—specifically, a reduction in EBF
while maintaining lean body mass is desirable. In addition, certain
treatment modalities are associated with weight gain, including
endocrine therapy in breast and prostate cancer, and steroid
treatments used as an adjunct to many chemotherapy regimens
and as supportive care in many oncological emergencies
associated with advanced cancer. These factors highlight the
importance of investigating EBF and weight gain by treatment.
Added to this, methodology concerns, including sampling
selection bias, residual or unmeasured confounding factors,
reverse causation and collider bias, call into question the
epidemiological basis for the obesity paradox in this context.
EBF, skeletal muscle mass, surrogate measures and survivorship
A growing number of observational studies have relied on surrogate
measures of adiposity (e.g., body weight, BMI and waist circumfer-
ence), which do little to advance our understanding of how changes
in the key body composition parameters of EBF and skeletal muscle
mass might independently influence cancer survivorship. Caan
et al.31 argued that people who are overweight or obese generally
have higher levels of skeletal muscle than people of lower weight,
thus decreasing the risk of disease recurrence, surgical complications
and treatment-related toxicities associated with lower skeletal
muscle mass. It is, however, important to analyse appropriately for
age when classifying sarcopenia.32 When age is taken into
consideration, sarcopenic obesity— skeletal muscle depletion
despite high BMI—is reported to be prevalent in approximately
one-tenth of patients with advanced solid tumours, and is
independently associated with increased complication and mortality
rates across multiple cancer sites and treatment plans.33 Further-
more, in non-metastatic breast-cancer patients, computer-
tomography-derived measures of sarcopenia and total adiposity at
diagnosis were shown to be independently associated with overall
mortality over 6 years of follow-up, whereas BMI was not.34 These
results further underline the need to assess body composition rather
than rely on BMI in order to guide best advice for nutritional and
physical activity survivorship plans.
THE EFFECT OF EBF ON CANCER TREATMENT
The effects of EBF and weight-management interventions on
treatment outcomes, post-treatment morbidity and mortality
might differ between cancer types, and many important research
questions in this arena need to be answered.35 For example, the
impact of high BMI (reflecting EBF) on the efficacy of local and
systemic cancer therapies and the associated side effects in the
context of optimising long-term treatment plans is largely
understudied.36 A systematic review of the effect of obesity on
toxicity in women treated with chemotherapy in early-stage breast
cancer concluded that obese patients tolerate chemotherapy
better than lean patients.37 However, it was acknowledged by the
authors that this observation ‘may be confounded by poorly
specified dose-capping practices and the use of haematopoietic
growth factors' (which may have been used more frequently in
obese patients if clinicians perceived that these patients were at a
higher risk of myelosuppression due to higher absolute drug
doses).
A narrative review34 evaluating the effect of obesity on a wide
variety of oncology-treatment modalities highlighted a number of
points. First, technical challenges posed by high BMI might
adversely impact surgical morbidity outcomes (e.g., increased risk
of surgical site infections, reduced lymph-node harvest and
increased risk of margin positivity). Second, the potential exists
for suboptimal chemotherapy dosing; this is associated with
capping chemotherapy in obese patients to avoid toxicity and
might be a driver of poor prognostic outcomes. Conversely,
however, the efficacy of immune-checkpoint inhibition could
potentially be enhanced in patients who are obese. These
checkpoints moderate the immune response and the ability to
impact on tumour cells. Immunotherapy agents have been
developed for a number of cancers and the importance of these
in the overweight and obese is emerging.34
The review also raised an important question: does EBF
influence outcomes directly through cancer biology (such as via
the effects of adipose tissue on the levels of oestrogens, insulin,
insulin-like growth factors and other adipokines to create a pro-
inflammatory environment that encourages carcinogenesis) or are
the adverse outcomes of EBF mediated through indirect pathways
(e.g., chemotherapy dosing) that result in suboptimal treatment?
Interpreting the results of observational studies investigating the
effect of EBF on mortality and survival
Various studies have investigated the impact of EBF on a range of
cancer outcomes in many cancer types but, to date, the evidence
on overall survivorship risks is inconclusive. In summarising these
studies (e.g., in breast cancer), the World Cancer Research Fund
(WCRF) Continuous Update Project (CUP) panel10 developed a
framework for interpreting the effect of anthropometric measures
on mortality and survival at three key time points: pre-diagnosis of
cancer, peri-diagnosis/peri-treatment, and during survivorship (see
Table 1). Exposures (diet, physical activity and body composition)
measured prior to cancer diagnosis are anticipated to influence
cancer incidence and overall mortality via an effect on cancer
biology. The main biological mechanisms of interest (metabolic
regulators including insulin, insulin-like growth factor 1, adipo-
kines, inflammation-related molecules and steroid hormones, as
well as the cellular and structural components of the tumour
microenvironment, including adipose tissue)38 are likely to have
long-term impacts without appropriate interventions.
Interventions based on these exposures are thus relevant to
cancer-prevention strategies, but further evidence will be required
for weight-management policies in cancer survivors. Anthropo-
metric measurements taken at the time of cancer diagnosis can be
assessed as prognostic indicators, but must be interpreted in the
context of the cancer type, stage and patient performance status,
as well as the timing of measurements in relation to treatment
modalities. The impact of body composition on therapy-related
toxicities is equally important in patients with advanced cancer
where the goals of systemic therapies are to improve and
maintain quality of life whilst also extending life expectancy. This
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area is poorly addressed in the current literature and represents an
important unmet research need. However, as recent weight loss is
a frequent presentation of advanced-stage cancer (reverse
causality), there is a need to analyse the association of body
mass and survival in advanced-stage patients separately to that of
patients with early-stage disease who are less likely to present
with weight loss and will have a longer median survival time.
Assessment of body mass and size after treatment also needs
attention in relation to the type of treatment received for different
tumour types and any associated toxicities, and an awareness of
selection against patients with rapid disease progression who
have not survived to this point.
Weight-loss trials: a gap in the evidence
Despite the limitations of observational data, the consistency and
magnitude of associations between EBF/weight gain and survival
outcomes for some cancers reported in systematic reviews and
meta-analyses support the need for intervention studies.27,39 To
date, weight-loss intervention studies have predominantly been
carried out in breast-cancer survivors. A large-scale dietary
intervention trial (low fat, high fruits and vegetables) in women
with early-stage breast cancer—the Women’s Intervention Nutri-
tion Study (WINS)—was successful in supporting women to lose
weight, with indications of lower cancer recurrence in the
intervention group, notably in women with oestrogen-receptor
(ER)-negative disease.40 Furthermore, a growing number of short-
term trials have demonstrated the effects of intentional weight
loss on blood-borne biomarkers of cancer and cardiometabolic
risk, including changes in serum sex hormones,41 inflammation
markers42 and insulin sensitivity.43 A small number of ongoing
intentional weight-loss trials are also ongoing in breast-cancer
survivors44–46 and are expected to report on survival and
associated outcomes over the next decade. Weight-loss trials
have also been undertaken in endometrial cancer survivors.47
However, a 2018 Cochrane review48 concluded that there is
insufficient high-quality evidence to determine the effect of
interventions on survival, quality of life or cardiovascular events.
The authors highlighted problems of high risk of bias by failing to
blind personnel and outcome assessors, and significant losses to
follow-up. They also emphasised the need for adequately
powered trials with a follow-up of at least 5–10-year duration.
Importantly, no trial has yet established the effect of intentional
weight loss following a cancer diagnosis on mortality, and many
gaps in our understanding of how to optimise such interventions
remain. The optimal contributions of diet composition, caloric
intake, amount and nature of physical activity (including sedentary
time) for promoting loss of EBF and avoiding weight gain49 are
important considerations for future intervention research. Further-
more, the effects of weight- management interventions on
treatment-related side effects, as well as bone health, physical
function, psychosocial issues and quality of life, have not been
clearly defined for many cancers, and intervention studies are
needed to address these important issues.48
Weight-management strategies in overweight and obese
cancer survivors might also have a role to play in the prevention
of non-cancer deaths—for some individual patients, the presence
of EBF might also confer a poorer prognosis for survival from non-
cancer disease. For example, cancer patients who also have
diabetes have a decreased overall survival compared with cancer
patients without diabetes, in part because they are at increased
risk of non-cancer (mainly cardiovascular) deaths,50 which might
be further increased by certain treatments (e.g., anthracycline
chemotherapy).
Whilst the case for examining the impact of weight manage-
ment can be made from current evidence, the design of
programmes to capture the magnitude of effect and possible
negative consequences need to be fully explored.
TIME TO INVEST IN INTERVENTION RESEARCH FOR EBF?
Developing and testing interventions for promoting the inten-
tional loss of EBF and maintaining skeletal muscle mass require a
number of considerations, which we outline below.
Optimum timing of interventions
The optimum window for weight-loss interventions in cancer
survivors needs careful consideration. Treatment for cancer is
increasingly being delivered over longer periods of time and is
multimodal in nature; acute side effects, including unintentional
gains in body weight and changes in body composition, which
might negatively influence cancer outcomes and response to
treatment, are not uncommon.51 Of early-stage breast-cancer
patients receiving chemotherapy, 30–60% gain significant weight.
This weight gain involves losing skeletal muscle while gaining
adiposity52 and adversely impacts quality of life and overall
health.53 Young breast-cancer patients can gain over 5% body
Table 1. Interpretation of studies evaluating anthropometric measures on mortality and survival.
When measure
determined
Time zero in modelling Endpoint
terminology
Interpretation
Pre-diagnosis At cohort entry Cancer mortality Cancer mortality and all-cause mortality among cohort participants is
conditional on the exposure influencing cancer incidence, subsequent
treatment and cancer biology. These studies indicate the burden of death
attributed to anthropometric exposures (e.g., EBF).
The findings have implications for public health and global policy, but do
not have direct implications for weight- management intervention
strategies in cancer survivors.
Peri-diagnosis/
peri-treatment
At diagnosis or start of
treatment
Survival These studies are best considered as prognostic studies and should be
interpreted in light of adjustment for other major cancer prognostic
factors, including disease stage, treatment, and performance status. There
is often a proportion of patients who have lost weight due to cancer and
treatment (reverse causality), with downward BMI-category migration.
These studies add some evidence to directly inform weight- management
policies in cancer survivors.
Post treatment During survivorship,
e.g., at year 1
Survival These studies in patients have already survived treatment. Survival
endpoints are important but so are quality of life, late effects of cancer
treatment, avoidance of other cancer events and other diseases.
These studies add evidence to directly inform weight- management
policies in cancer survivors.
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weight in the first 12 months after diagnosis,54 which is associated
with changes in eating habits resulting from emotional stress as
well as the side effects of treatments (e.g., steroids and
chemotherapy-induced menopause, cancer-related fatigue and
reduced physical activity). Clearly, interventions that provide the
support needed to help patients avoid or limit unintentional
weight gain during treatment and/or facilitate EBF loss following
completion of treatment whilst maintaining adequate levels of
physical activity would be valuable adjuncts to curative cancer-
care pathways.
Changes in nutritional and metabolic status that influence
sarcopenia and cachexia must be addressed with the appropriate
nutritional support throughout treatment,11 irrespective of body
weight. For this reason, intentional weight-loss interventions
might be challenging and possibly inadvisable for some cancer
populations during the period of treatment, and the post-
treatment period is likely to offer a more practical time
frame. For example, chemoradiation treatment for patients
with head and neck cancers is already associated with a significant
incidence of weight loss and malnutrition, and patients
frequently require nutritional support during treatment, while
patients with upper gastrointestinal cancer often present with
rapid weight loss owing to dysphagia and, again, management
should be focussed on optimising nutritional intake prior to and
during treatment.
The study population
Careful consideration needs to be given to the study population,
including age, location, ethnicity, co-morbidities, primary cancer
site and stage of disease when designing weight-loss interven-
tions aimed at optimising efficacy and effectiveness. Trials to
investigate the benefits of intentional weight loss are most likely
to be acceptable to clinicians and patients in cancer populations
where there is evidence that EBF is associated with second cancer
risk or poorer outcome. In addition, low frequency of rapid weight
loss at presentation or associated with common first-line
treatment strategies will also make intentional weight-loss
programmes seem more appropriate. Patients with early-stage
presentations of breast, endometrial, colorectal and prostate
cancers might meet these requirements. Close attention must
also be paid to the biology of the disease, particularly within
metastatic cancer populations: patients with ER-positive meta-
static breast cancer and no visceral disease frequently have an
indolent disease course that can be managed predominantly by
endocrine therapy over many years and constitute, potentially, a
more appropriate population for weight-intervention strategies
than patients with triple-negative metastatic disease who
frequently develop rapid disease progression, leading to failure
of vital organs.
Outcome measures
Outcome measures in weight-management trials should include
those that are patient-reported as well as clinically reported.
Patient-reported outcomes (PROMS) include measures of quality
of life, which can be broadly categorised into five groups: general
health and well-being, physical factors (e.g., weight loss),
symptoms (e.g., pain, nausea and fatigue), psychological factors
(e.g., anxiety, insomnia and self-esteem) and social factors (e.g.,
relationships and work). Clinical outcome measures might vary
according to cancer site and treatment regimens, but should
include those assessing acute and long-term side effects of
local and systemic therapies (e.g., lymphoedema volumes,
fatigue scores, bone mineral density and cardiac ejection
fractions) as well as cancer outcomes (locoregional and distant
disease-free survival) and overall survival. Circulating biomarkers
and surrogate endpoints (e.g., adenomas, breast density55) should
be used alongside PROMS to gain an overview of the relevant
biological and well-being perspectives allowing clinical, scientific
and person-specific characteristic insights into the impact of
interventions.
Minimising heterogeneity/standardising outcomes
The sources of heterogeneity need to be carefully considered and
controlled for in the design of weight-management studies, and/
or considered during the analytic phase. The potential for clinical
heterogeneity in outcomes exists according to disease subtype,
stage and grade, as well as in the treatment received, but
methodological heterogeneity in the way outcomes are defined
can also occur. It is plausible that patients with different cancers
might respond differently to weight- management interventions
—notably, those with obesity-related cancers versus non-obesity-
related cancers. Standardising outcomes is important for consis-
tency and for comparison across trials, and allows incorporation
into meaningful meta-analyses. To improve the definition and
measurement of outcomes, the Core Outcome Measures in
Effectiveness Trials (COMET) initiative56 provides guidance for
researchers by advocating a standardised set of outcomes that
should be measured and reported, as a minimum, in all clinical
trials of health, including weight management. Examples listed in
Table 2 illustrate the breadth of outcomes, similarities and
differences by site used by different research teams, and highlight
the need for further work on agreed core outcomes. Additionally,
incorporation of the accumulating data to optimally predict
obesity treatment (ADOPT)57 biological domain framework could
advance the understanding of individual variability in response to
adult obesity treatments and explore the physiological mechan-
isms that could influence cancer recurrence.
Weight-management intervention design
The design of weight-management intervention (in terms of dose
and duration) needs to be driven by practicalities as well as the
desired magnitude of change in body composition (e.g., body
fatness and skeletal muscle mass)—this approach has the greatest
likelihood of positively influencing patient and clinical out-
comes.58 Caloric intake is the cornerstone of weight loss, but
regular physical activity and structured exercise programmes have
important roles to play in all aspects of weight management.59
Importantly, physical activity and exercise can preserve skeletal
muscle mass during dietary-induced fat loss,60,61 thereby helping
to protect against the adverse impact of sarcopenia on cancer-
survival outcomes31,62 and increasing total daily energy output.63
Physical activity post diagnosis is associated with improved
survival outcomes for patients with breast, colorectal or prostate
cancer.64 Furthermore, an international consensus statement
concluded that sufficient evidence now exists to show that
regular exercise improves several cancer-related health outcomes,
including anxiety, depressive symptoms, fatigue, physical func-
tioning and health-related quality of life in cancer survivors.65
The growing body of effective weight-loss programmes
(BRRIDE,66 DIRECT67 and DPP68) that have achieved clinically
relevant changes (e.g., diabetes remission) in cancer and non-
cancer patients provides a good starting point for intervention
design. However, translating these programmes into cancer-
survivorship populations might require significant patient involve-
ment to ensure that the components (notably, dietary and
structured exercise or physical activity goals) can be achieved by
those with a wide range of abilities, disabilities, emotional needs,
available time and financial circumstances. Furthermore, insights
from behavioural science69 provide guidance for embedding
strategies to support long-term behavioural change, which are
anchored in robust psychological theory and evidence-based
behaviour-change techniques. The potential of remote support
offered by digital and other ‘smart’ technologies (in particular, to
people with co-morbid conditions such as cognitive and sight
impairments) provides further scope to engage with vulnerable
people, including those living in rural communities.
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Feasibility studies
Finally, feasibility trials are an essential starting point for definitive
randomised controlled trials with respect to gauging patient
acceptability and tolerability, and gleaning valuable qualitative
and quantitative data about recruitment, implementation, reten-
tion and indicative effects. One novel method that could
Table 2. Range of core outcomes relevant in clinical trials of weight management.




Description of core outcome sets
Breast cancer69 All treatments 27 Survival and disease control: Overall survival, death attributed to breast cancer and
recurrence-free survival
Degree of health: Overall well-being, physical functioning, emotional functioning,
cognitive functioning, social functioning, ability to work, anxiety, depression,
insomnia, financial impact, pain, fatigue, sexual function and body image
Patients treated with surgery and/or radiotherapy: Satisfaction with breast(s), arm
symptoms, breast symptoms and lymphoedema
Patients with systemic therapy: Vasomotor symptoms, peripheral neuropathy,
vaginal symptoms and arthralgia
Disutility of care: Reoperation owing to involved margins, severity of acute
complications (based on the assessment of postoperative outcome scores)
Prostate cancer70 Localised 19 12 apply to all interventions: Death from prostate cancer, death from any cause,
local disease recurrence, distant disease recurrence/metastases, disease progression,
need for salvage therapy, overall quality of life, stress urinary incontinence, urinary
function, bowel function, faecal incontinence and sexual function
Seven were intervention-specific: Perioperative deaths (surgery), positive surgical
margin (surgery), thromboembolic disease (surgery), bothersome or symptomatic
urethral or anastomotic stricture (surgery), need for curative treatment (active
surveillance), treatment failure (ablative therapy) and side effects of hormonal
therapy (hormone therapy)
Colorectal cancer71 Surgery 12 Oncological outcomes: Long-term survival, cancer recurrence and resection margins
Operative outcomes: Anastomotic leak, perioperative survival, surgical site infection,
stoma rates and complications and conversion to open operation (where
appropriate)
Quality of life: Physical function, sexual function, faecal incontinence and faecal
urgency
Stage 1
Stage 1: PRODIET RCT (n = 133)
Stage 2: GWAS (n = 72,729)












Randomised effects of lycopene
and green tea vs placebo on
metabolites
Stage 2
Fig. 2 Two-step Mendelian Randomisation procedure: integration of feasibility randomised controlled trial (RCT) results with MR to
predict the long-term effect of interventions. Introduction to Mendelian randomisation: Mendelian randomisation is a form of instrumental
variable analysis that uses genetic variants as instruments to examine the causal effects of modifiable exposures on outcomes of interest. This
method depends on the existence of genetic variants that are robustly associated with metabolite levels. In the example outlined here, the
results of a feasibility RCT of dietary interventions for the prevention of prostate cancer were carried forward to a large-scale Mendelian
randomisation analysis to infer the causal effect of the interventions on prostate cancer risk via intermediate metabolites. Step 1 assessed the
randomised effects of lycopene and green-tea consumption for 6 months versus placebo on 159 serum metabolic traits, quantified by nuclear
magnetic resonance (NMR), amongst 133 men enrolled in the ProDiet randomised controlled trial. Step 2 used Mendelian randomisation to
assess the effects of those metabolic traits altered by the intervention on prostate cancer risk, using genome-wide association studies (GWAS)
summary statistics from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)
consortium. The lycopene intervention lowered circulating levels of pyruvate, a change that the Mendelian randomisation analysis suggested
was associated with decreases in prostate cancer risk (a genetically instrumented SD increase in pyruvate increased the odds of prostate
cancer by 1.29 (1.03, 1.62, P= 0.027)). Lycopene lowered the levels of pyruvate, which our Mendelian randomisation analysis suggests may be
causally related to reduced prostate cancer risk. By combining the results of a feasibility study with Mendelian randomisation, it has been
possible to identify potential intermediate mechanisms through which interventions might be influencing cancer risk (see 767,68 (step 2)).
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transform the interpretation of feasibility trials is the use of
Mendelian randomisation. In this context, feasibility studies can
estimate the intervention effects on intermediate endpoints that
might be on the causal pathway to clinical outcomes. Using a two-
step process, the results of small-scale feasibility studies can be
used to inform much larger-scale two-sample Mendelian rando-
misation studies. This approach could provide novel insight into
the causal effects of an intervention on important intermediate
endpoints and possible long-term clinical endpoints (see Fig. 2). In
this way, Mendelian randomisation can then be used alongside
feasibility studies to optimise intervention development and
delivery, including more accurate outcome predictions for fully
powered conventional randomised controlled trials,70 as outlined
in Fig. 2.71
CONCLUSIONS
It is timely to extend our knowledge of weight management by
moving from epidemiology studies to interventional research, as it
relates to EBF in the context of cancer treatment and survivorship.
This increased knowledge will improve our understanding of the
health benefits to be gained from optimising body composition in
people living with and beyond common cancers, who constitute a
significant health burden worldwide. Interventions need to be
complex but pragmatic in design, while encompassing multi-
disciplinary methodological approaches aimed at improving our
understanding of causal mechanisms. These endeavours are
urgently needed to develop evidence-based strategies for mitigat-
ing the adverse impact of EBF in a growing global population of
cancer survivors67 living in increasingly obesogenic societies.
THE UK NIHR CANCER AND NUTRITION COLLABORATION
(POPULATION HEALTH STREAM)
Annie Anderson14, Rebecca Beeken15, Janet Cade16, Amanda Cross17, Angela King18,
Richard Martin19, Giota Mitrou20, Elio Riboli21, John Saxton22, Andrew Renehan23
14Public Health Nutrition, Centre for Research into Cancer Prevention and Screening,
University of Dundee, Dundee, UK; 15Yorkshire Cancer Research University Academic
Fellow, University of Leeds, Leeds, UK; 16Nutritional Epidemiology and Public Health,
University of Leeds, Leeds, UK; 17Cancer Epidemiology, Imperial College London,
London, UK; 18Public Representative, NIHR Cancer and Nutrition Collaboration,
Southampton, UK; 19Clinical Epidemiology, University of Bristol, Bristol, BRC, UK;
20Research Funding & Science External Relations, WCRF, London, UK; 21Cancer
Epidemiology and Prevention, Imperial College London, London, UK; 22Clinical
Exercise Physiology, Northumbria University, Newcastle, UK and 23Cancer Studies and
Surgery, University of Manchester; Honorary Consultant Colorectal Surgeon,
Manchester, UK
ACKNOWLEDGEMENTS
The authors thank Ms Jill Hampton, Mrs Mary Burke for the paper coordination and
preparation and Ms Fiona Davies for organisation of meetings and discussion
sessions.
AUTHOR CONTRIBUTIONS
A.S.A. led the paper drafting, original concept, paper structure and drafting, while
R.M.M., A.G.R., J.C., E.R.C., A.J.C., C.G., L.K., A.K., E.R., C.S. and J.M.S. were involved in the
original concept, paper structure and drafting. All authors approved the final version
of the paper.
ADDITIONAL INFORMATION
Ethics approval and consent to participate Not applicable.
Consent to publish Not applicable.
Data availability Not applicable.
Competing interests R.M.M. reports grants from CRUK, during the conduct of the
study. J.C. reports that she is the director of Dietary Assessment Ltd. E.R.C. reports
other from SECA, personal fees from Roche, personal fees from Lilly, personal fees
from Pfizer, personal fees from Novartis, personal fees from Astra-Zeneca and
personal fees from Nanostring, outside the submitted work. C.S. reports personal fees
from Boehringer Ingelheim, personal fees from Eli Lilley and Company and personal
fees from Chugai, outside the submitted work. The remaining authors declare no
competing interests.
Funding information This work was supported by the NIHR Cancer and Nutrition
Collaboration. The views expressed are those of the author(s) and not necessarily
those of the NIHR or the Department of Health and Social Care Funding. R.M.M. is
supported by a Cancer Research UK programme grant (C18281/A19169) and by the
National Institute for Health Research (NIHR) Bristol Biomedical Research Centre. The
National Institute for Health Research (NIHR) Bristol Biomedical Research Centre is
funded by the National Institute for Health Research and is a partnership between
University Hospitals Bristol NHS Trust and the University of Bristol. The views
expressed are those of the author(s) and not necessarily those of the NIHR or the
Department of Health and Social Care. A.G.R. is supported by the Manchester NIHR
Biomedical Research Centre (IS-BRC-1215-20007). C.S. is partly funded by the National
Institute for Health Research (NIHR) Biomedical Research Centre at The Royal
Marsden NHS Foundation Trust and the Institute of Cancer Research, London.
Note This work is published under the standard license to publish agreement. After
12 months the work will become freely available and the license terms will switch to
a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. “DCCPS: OCS: About Cancer Survivorship Research: Survivorship Definitions”.
(Office of Cancer Survivorship of the US National Cancer Institute, 2006).
2. Macmillan cancer Support. Cancer cash crisis—counting the cost of care
beyond treatment. https://www.macmillan.org.uk/documents/campaigns/
cancercashcrisisreport-macmillandecember2015.pdf (2015).
3. Maddams, J., Utley, M. & Møller, H. Projections of cancer prevalence in the United
Kingdom, 2010–2040. Br. J. Cancer 107, 1195–1202 (2012).
4. Allemani, C. & Coleman, M. P. Public health surveillance of cancer survival in the
United States and worldwide: The contribution of the CONCORD programme.
Cancer 123, 4977–4981 (2017).
5. World Health Organisation. Obesity and Overweight. https://www.who.int/news-
room/fact-sheets/detail/obesity-and-overweight (WHO, 2018).
6. International Agency for Research on Cancer. Absence of Excess Body Fatness.
http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-
Prevention/Absence-Of-Excess-Body-Fatness-2018 (IARC, 2018).
7. Hopkins, B. D., Goncalves, M. D. & Cantley, L. C. Obesity and cancer mechanisms:
cancer metabolism. J. Clin. Oncol. 34, 4277–4283 (2016).
8. Quail, D. F. & Dannenberg, A. J. The obese adipose tissue microenvironment in
cancer development and progression. Nat. Rev. Endocrinol. Mar. 15, 139–154
(2019).
9. Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E. et al. Caloric
restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 30,
147–160 (2016).
10. World Cancer Research Fund. Cancer survivors: evidence on survivors of breast
and other cancers. https://www.wcrf.org/dietandcancer/cancer-survivors (2018).
11. Arends, J., Bachmann, P., Baracos, V., Barthelemey, N., Bertz, H., Bozzetti, F. et al.
ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36, 11–48 (2017).
12. El-Shami, K., Oeffinger, K. C., Erb, N. L., Willis, A., Bretsch, J. K., Pratt-Chapman, M. L.
et al. American cancer society colorectal cancer survivorship care guidelines. CA:
Cancer J. Clin. 65, 428–455 (2015).
13. Anderson, A. S., Caswell, S., Wells, M. & Steele, R. J. Obesity and lifestyle advice in
colorectal cancer survivors—how well are clinicians prepared? Colorectal Dis. 15,
949–957 (2013).
14. Koutoukidis, D. A., Lopes, S., Fisher, A., Williams, K., Croker, H. & Beeken, R. J.
Lifestyle advice to cancer survivors: a qualitative study on the perspectives of
health professionals. BMJ Open 8, e020313 (2018).
15. Markham, M. J., Wachter, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W.
et al. Clinical cancer advances 2020: annual report on progress against cancer
from the American Society of Clinical Oncology. J. Clin. Oncol. 38, 10, 1081 (2020).
16. Cao, F., Li, F., Shi, L., Zhang, L., Ma, T. & Zhang, G. Mortality trends of colorectal
cancer among overweight patients at the global and national levels. Int. J. Col-
orectal Dis. https://doi.org/10.1007/s00384-019-03371-6 (2019)
Cancer survivorship, excess body fatness and weight-loss. . .
AS Anderson et al.
7
17. Chan, D. S., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A.
et al. Body mass index and survival in women with breast cancer-systematic
literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 25,
1901–1914 (2014).
18. Westhoff, E., Witjes, J. A., Fleshner, N. E., Lerner, S. P., Shariat, S. F., Steineck, G.
et al. Body mass index, diet-related factors, and bladder cancer prognosis: a
systematic review and meta-analysis. Bladder Cancer 4, 91–112 (2018).
19. Cao, Y. & Ma, J. Body mass index, prostate cancer-specific mortality, and bio-
chemical recurrence: a systematic review and meta-analysis. Cancer Prev. Res. 4,
486–501 (2011).
20. Gupta, A., Das, A., Majumder, K., Arora, N., Mayo, H. G., Singh, P. P. et al. Obesity is
independently associated with increased risk of hepatocellular cancer-related
mortality: a systematic review and meta-analysis. Am. J. Clin. Oncol. 41, 874–881
(2018).
21. Park, Y., Peterson, L. L. & Colditz, G. A. The plausibility of obesity paradox in
cancer-point. Cancer Res. 78, 1898–1903 (2018).
22. Cespedes Feliciano, E. M., Kroenke, C. H. & Caan, B. J. The obesity paradox in
cancer: how important is muscle? Annu. Rev. Nutr. 38, 357–379 (2018).
23. Walter, V., Jansen, L., Hoffmeister, M., Ulrich, A., Roth, W., Bläker, H. et al. Prog-
nostic relevance of prediagnostic weight loss and overweight at diagnosis in
patients with colorectal cancer. Am. J. Clin. Nutr. 104, 1110–1120 (2016).
24. Van Arsdale, A., Miller, D. T., Kuo, D. Y., Isani, S., Sanchez, L. & Nevadunsky, N. S.
Association of obesity with survival in patients with endometrial cancer. Gynecol.
Oncol. 154, 156–162 (2019).
25. Wang, J., Xu, H., Zhou, S., Wang, D., Zhu, L., Hou, J. et al. Body mass index and
mortality in lung cancer patients: a systematic review and meta-analysis. Eur. J.
Clin. Nutr. 72, 4–17 (2018).
26. Arem, H. & Irwin, L. Obesity and endometrial cancer survival:a systematic review.
Int J. Obes. 37, 634–639 (2013).
27. Christensen, J. F., Simonsen, C. & Hojman, P. Exercise training in cancer control
and treatment. Comprehensive Physiol. 9, 165–205 (2019).
28. Playdon, M. C., Bracken, M. B., Sanft, T. B., Ligibel, J. A., Harrigan, M. & Irwin, M. L.
Weight gain after breast cancer diagnosis and all-cause mortality: systematic
review and meta-analysis. J. Natl Cancer Inst. 107, djv275 (2015).
29. Otto, S. J., Korfage, I. J., Polinder, S., van der Heide, A., de Cries, E., Rietjens, J. A. C.
et al. Association of change in physical activity and body weight with quality of
life and mortality in colorectal cancer: a systematic review and meta-analysis.
Support Care Cancer 23, 1237–1250 (2015).
30. Doleman, B., Mills, K., Lim, 3, Zelhart, M. & Gagliardi, G. Body mass index and
colorectal cancer prognosis: a systematic review and meta-analysis. Tech. Colo-
proctol. 20, 517–535 (2016).
31. Caan, B. J., Cespedes Feliciano, E. M. & Kroenke, C. H. The importance of body
composition in explaining the overweight paradox in cancer-counterpoint.
Cancer Res. 78, 1906–1912 (2018).
32. Parkin, E. & Renehan, A. G. Need to distinguish the term sarcopenia from risk
stratification derived from muscle parameters. J. Clin. Oncol. 36, 2128–2129
(2018).
33. Baracos, V. E. & Arribas, L. Sarcopenic obesity: hidden muscle wasting and its
impact for survival and complications of cancer therapy. Ann. Oncol. 29, ii1–ii9
(2018).
34. Caan, B. J., Cespededs Feliciano, E. M., Prado, C. M., Alexeeff, S., Kroenke, C. H.,
Bradshaw, P. et al. Association of muscle and adiposity measured by computed
tomography with survival in patients with nonmetastatic breast cancer. JAMA
Oncol. 4, 798–804 (2018).
35. Slawinski, C. G. V., Barriuso, J., Guo, H. & Renehan, A. G. 2020 obesity and cancer
treatment outcomes: interpreting the complex evidence clinical oncology. Clin.
Oncol. 32, 591–608 (2020).
36. Parekh, N., Chandran, U. & Bandera, E. V. Obesity in cancer survival. Annu. Rev.
Nutr. 32, 311–342 (2012).
37. Protani, M., Coory, M. & Martin, J. H. Effect of obesity on survival of women with
breast cancer: systematic review and meta-analysis. Breast Cancer Res. Treat. 123,
627–635 (2010).
38. Doerstling, S. S., O’Flanagan, C. H. & Hursting, S. D. Obesity and cancer meta-
bolism: a perspective on interacting tumor–intrinsic and extrinsic factors. Front.
Oncol. 7, 216 (2017).
39. Doleman, B., Mills, K. T., Lim, S., Zelhart, M. D. & Gagliardi, G. Body mass index and
colorectal cancer prognosis: a systematic review and meta-analysis. Tech. Colo-
proctol. 20, 517–535 (2016).
40. Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy,
M. K. et al. Dietary fat reduction and breast cancer outcome: interim efficacy
results from the Women’s Intervention Nutrition Study. J. Natl Cancer Inst. 98,
1767–1776 (2006).
41. Rock, C. L., Pande, C., Flatt, S. W., Ying, C., Pakiz, B., Parker, B. A. et al. Favorable
changes in serum estrogens and other biologic factors after weight loss in breast
cancer survivors who are overweight or obese. Clin. Breast Cancer 13, 188–195
(2013).
42. Harrigan, M., Cartmel, B., Loftfield, E., Sanft, T., Chagpar, A. B., Zhou, Y. et al.
Randomized trial comparing telephone versus in-person weight loss counseling
on body composition and circulating biomarkers in women treated for breast
cancer: the lifestyle, exercise, and nutrition (LEAN) study. J. Clin. Oncol. 34,
669–676 (2016).
43. Pakiz, B., Flatt, S. W., Bardwell, W. A., Rock, C. L. & Mills, P. J. Effects of a weight loss
intervention on body mass, fitness, and inflammatory biomarkers in overweight
or obese breast cancer survivors. Int. J. Behav. Med. 18, 333–341 (2011).
44. Ligibel, J. A., Barry, W. T., Alfano, C. M., Hershman, D. L., Irwin, M. L., Neuhouser, M.
et al. The breast cancer weight loss (BWEL) trial: randomized phase III trial
evaluating the role of weight loss in adjuvant treatment of overweight and obese
women with early-stage breast cancer (Alliance A011401). J. Clin. Oncol. 36,
TPS598–TPS598 (2018).
45. Rack, B., Andergassen, U., Neugebauer, J., Salmen, J., Hepp, P., Sommer, H. et al.
The German SUCCESS C Study—the first european lifestyle study on breast
cancer. Breast Care 5, 395–400 (2010).
46. Villarini, A., Pasanisi, P., Traina, A., Mano, M. P., Bonanni, B., Panico, S. et al. Lifestyle
and breast cancer recurrences: the DIANA-5 trial. Tumori 98, 1–18 (2012).
47. Kitson, S., Ryan, N., MacKintosh, M. L., Edmondson, R., Duffy, J. M. & Crosbie, E. J.
Interventions for weight reduction in obesity to improve survival in women with
endometrial cancer. Cochrane Database Syst. Rev. 2, CD012513, https://doi.org/
10.1002/14651858.CD012513.pub2 (2018).
48. Jackson, S. E., Heinrich, M., Beeken, R. J. & Wardle, J. Weight loss and mortality in
overweight and obese cancer survivors: a systematic review. PloS ONE 12,
e0169173 (2017).
49. Demark-Wahnefried, W., Schmitz, K. H., Alfano, C. M., Bail, J. R., Goodwin, P. J.,
Thomson, C. A. et al. Weight management and physical activity throughout the
cancer care continuum. CA Cancer J. Clin. 68, 64–89 (2018).
50. Renehan, A. G., Alam, N. N. & Sperrin, M. Interaction between co-morbidities and
cancer survival. Eur. J. Epidemiol. 34, 1103–1105 (2019).
51. Martin, L. P., Senesse, I., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C. et al.
Diagnostic criteria for the classification of cancer-associated weight loss. J. Clin.
Oncol. 33, 90–99 (2015).
52. Vance, V., Mourtzakis, M., McCargar, L. & Hanning, R. Weight gain in breast cancer
survivors: prevalence, pattern and health consequences. Obes. Rev. 12, 282–294
(2011).
53. Makari-Judson, G., Braun, B., Jerry, D. J. & Mertens, W. C. Weight gain following
breast cancer diagnosis: implication and proposed mechanisms. World J. Clin.
Oncol. 5, 272–282 (2014).
54. Gandhi, A., Copson, E., Eccles, D., Durcan, L., Howell, A., Morris, J. et al. Predictors
of weight gain in a cohort of premenopausal early breast cancer patients
receiving chemotherapy. Breast 45, 1–6 (2019).
55. Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M.,
Funkhouser, W. K. et al. Molecular biomarkers for the evaluation of colorectal
cancer: guideline from the American Society for Clinical Pathology, College of
American Pathologists, Association for Molecular Pathology, and the American
Society of Clinical Oncology. J. Clin. Oncol. 35, 1453–1486 (2017).
56. Williamson, P. R., Altman, D. G., Bagley, H., Barnes, K. L., Blazeby, J. M., Brookes, S.
T. et al. The COMET handbook: version 1.0. Trials 18, 280 (2017).
57. Rosenbaum, M., Agurs-Collins, T., Bray, M. S., Hall, K. D., Hopkins, M., Laughlin, M.
et al. Accumulating data to optimally predict obesity treatment (ADOPT):
recommendations from the biological domain. Obesity 26, S25–S34 (2018).
58. Ballard-Barbash, R., Hunsberger, S., Alciati, M. H., Blair, S. N., Godwin, P. J.,
McTiernan, A. et al. Physical activity, weight control, and breast cancer risk and
survival: clinical trial rationale and design considerations. J. Natl Cancer Inst. 101,
630–643 (2009).
59. Chaput, J. P., Klingenberg, L., Rosenkilde, M., Gilbert, J. A., Tremblay, A. & Sjödin, A.
Physical activity plays an important role in body weight regulation. J. Obes. pii:
360257. https://doi.org/10.1155/2011/360257 (2011).
60. Ostendorf, D. M., Caldwell, A. E., Creasy, S. A., Pan, Z., Lyden, K., Bergouignan, A.
et al. Physical activity energy expenditure and total daily energy expenditure in
successful weight loss maintainers. Obesity 27, 496–504 (2019).
61. Poggiogalle, E., Migliaccio, S., Lenzi, A. & Donini, L. M. Treatment of body com-
position changes in obese and overweight older adults: insight into the phe-
notype of sarcopenic obesity. Endocrine 47, 699–716 (2014).
62. Caan, B. J., Cespedes Feliciano, E. M., Prado, C. M., Alexeeff, S., Kroenke, C. H.,
Bradhsaw, P. et al. Association of muscle and adiposity measured by computed
tomography with survival in patients with nonmetastatic breast cancer. JAMA
Oncol. 4, 798–804 (2018).
63. Stiegler, P. & Cunliffe, A. The role of diet and exercise for the maintenance of fat-
free mass and resting metabolic rate during weight loss. Sports Med. 36, 239–262
(2006).
Cancer survivorship, excess body fatness and weight-loss. . .
AS Anderson et al.
8
64. Friedenreich, C. M., Stone, C. R., Cheung, W. Y., Hayes, S. C. Physical activity and
mortality in cancer survivors: a systematic review and meta-analysis. JNCI Cancer
Spectr. 4, pkz080 (2019).
65. Campbell, K. L., Winters-Stone, K. M., Wiskemann, J., May, A. M., Schwartz, A. L.,
Courneya, K. S. et al. Exercise guidelines for cancer survivors: consensus state-
ment from international multidisciplinary roundtable. Med. Sci. Sports Exerc 51,
2375–2390 (2019).
66. Harvie, M., Wright, C., Pegington, M., McMullan, D., Mitchell, E., Martin, B., Cutler, R.
G. et al. The effect of intermittent energy and carbohydrate restriction v. daily
energy restriction on weight loss and metabolic disease risk markers in over-
weight women. Br. J. Nutr. 110, 1534–1547 (2013).
67. Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L. et al.
Primary care-led weight management for remission of type 2 diabetes (DiRECT):
an open-label, cluster-randomised trial. Lancet 391, 541–551 (2018).
68. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M.,
Walker, E. A. et al. Diabetes Prevention Program Research Group. Reduction in the
incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J.
Med. 346, 393–403 (2002).
69. Hoedjes, M., van Stralen, M. M., Joe, S. T. A., Rookus, M., van Leeuwen, F., Michie, S.
et al. Toward the optimal strategy for sustained weight loss in overweight cancer
survivors: a systematic review of the literature. J. Cancer Surviv. 11, 360–385
(2017).
70. Sandu, M. R., Beynon, R., Richmond, R., Ferreira, S. L. S., Hackshaw-McGeagh, L.,
Smith, G. D. et al. Two-step randomisation: applying the results of small feasibility
studies of interventions to large-scale Mendelian randomisation studies to
robustly infer causal effects on clinical endpoints. Preprint at https://doi.org/
10.20944/preprints201910.0276.v1 (2019).
71. Beynon, R., Richmond, R. C., Santos Ferreira, D. L., Ness, A. R., May, M., Davey, G. D.
et al. The ProtecT Study Group. The PRACTICAL consortium. Investigating the
effects of lycopene and green tea on the metabolome of men at risk of prostate
cancer: the ProDiet randomised controlled trial. Int. J. Cancer https://doi.org/
10.1002/ijc.31929 (2018).
Cancer survivorship, excess body fatness and weight-loss. . .
AS Anderson et al.
9
